Expanding Sales of Proprietary Products
First written in FY2018-Q1. 7 of 11 entries say "Advanced", first in FY2018. Latest entry: FY2026.
The whole theme swung hardest in 2020: 2 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Operating profit was ¥1,302 million, down 14.2%, due mainly to lower value added resulting from decreased sales of internally designed products.」
Lower sales of internally designed products emerged as a factor behind declines in consolidated value added and operating profit. Meanwhile, activities aimed at securing development and mass-production orders are continuing. - 2026-05-14AdvancedManagement plan
「Expand the manufacture and sale of internally developed products」
The company explicitly designated expanding the manufacture and sale of internally developed products in India as a priority business. - FY2024AdvancedAnnual report
「In its domestic business, the Company is pursuing the development of proprietary products. As new businesses, it is developing new products in the medical and ultrasound fields, as well as manufacturing and developing power electronics products such as chargers, DC-DC converters and inverters.」
The Company has expanded its internally developed product portfolio to include medical products, ultrasound products, chargers, DC-DC converters and inverters, and is pursuing manufacturing, development and sales expansion. - FY2022AdvancedAnnual report
「The Company is also pursuing product development in the medical field, including single-use injection needles, by applying its microfabrication technology.」
In addition to power electronics, the Company is continuing and expanding development of medical products using microfabrication technology as part of its internally developed product portfolio. - FY2021AdvancedAnnual report
「For the single-use injection needle (Quatron), sales of which began in the previous fiscal year, the Company developed proprietary automated assembly equipment to expand sales. Mass production is scheduled to begin around autumn 2021.」
For internally developed products, the Company completed development of automated assembly equipment to expand Quatron sales and indicates that mass production is scheduled to begin around autumn 2021. - FY2020AdvancedAnnual report
「In the New Business Division, the Company is pursuing initiatives to commercialize new products in the medical field and has begun sales, mainly in Europe, of a new syringe developed in-house.」
Regarding expansion of sales of internally developed products, the Company discloses specific progress in the form of beginning sales, mainly in Europe, of a new syringe developed in-house. - FY2019AdvancedAnnual report
「In the Development Business Division, the Company is pursuing development of new products using power electronics technology. It also established ASTI RESEARCH AND DEVELOPMENT VIETNAM CORPORATION in Vietnam on 24 December 2018 for research and development, product design and production equipment design, and is working on new technology themes and the development of engineers.」
To expand internally developed products, the Company is pursuing power electronics product development and has also established a research and development company in Vietnam. - FY2018AdvancedAnnual report
「In the Electronics Business Division, the Company began mass production of 200W chargers for electric vehicles in the power electronics field, which it has focused on in recent years. It also received a new order for stationary chargers for electric motorcycles and is preparing for mass production of these chargers together with 350W vehicle-mounted chargers.」
Regarding expansion of sales of internally developed products, the Company discloses specific progress: the start of mass production of 200W chargers for electric vehicles, a new order for chargers for electric motorcycles, and preparations for mass production of 350W vehicle-mounted chargers. - FY2018-Q3RestatedAnnual report
「In the final year of its medium-term management plan, the Group worked to secure profits by promoting further automation and streamlining of production processes, optimizing its production structure and focusing on expanding sales of internally developed products in order to achieve its target state.」
The Company continues to focus on expanding sales of internally developed products as a measure to secure profit. - FY2018-Q2RestatedAnnual report
「The Company pursued further automation and rationalization of processes, optimization of its production operations, and expansion of sales of internally developed products in order to secure profit.」
The Company continues to focus on expanding sales of internally developed products as a measure to secure profit. - FY2018-Q1First statedAnnual report
「The Company pursued further automation and rationalization of processes, optimization of its production operations, and expansion of sales of internally developed products in order to secure profit.」
The Company explicitly states for the first time that it is focusing on expanding sales of internally developed products as a measure to secure profit.